Literature DB >> 3519379

Heparin-induced thrombocytopenia.

J G Kelton.   

Abstract

Heparin-induced thrombocytopenia is the most frequent and the most important idiosyncratic haematological drug reaction. It is important for several reasons: first, because heparin is used so often, and the frequency of heparin-induced thrombocytopenia is high, the risk of a hospitalized patient developing heparin-induced thrombocytopenia is high. Second, heparin-induced thrombocytopenia poses a major therapeutic dilemma for the clinician - continue the heparin and risk a worsening of the thrombocytopenia, or stop the heparin and risk extension or embolism of the thrombus. Finally, a small subset of patients with heparin-induced thrombocytopenia develop the disastrous complication of heparin-induced thrombocytopenia plus arterial thrombosis. Some of these patients die. In this review, we will summarize some of the issues concerning heparin-induced thrombocytopenia, including its frequency, the various techniques used to diagnose the condition, its pathophysiology and approaches that can be used to manage patients with heparin-induced thrombocytopenia.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3519379     DOI: 10.1159/000215288

Source DB:  PubMed          Journal:  Haemostasis        ISSN: 0301-0147


  13 in total

Review 1.  Immunotoxic side-effects of drug therapy.

Authors:  J A Mitchell; E M Gillam; L A Stanley; E Sim
Journal:  Drug Saf       Date:  1990 May-Jun       Impact factor: 5.606

2.  [Implementing ambulatory prevention of thrombosis with low molecular weight heparin in plaster immobilization of the lower extremity].

Authors:  H J Kock; K P Schmit-Neuerburg; J Hanke; A Terwort; G Rudofsky; H Hirche
Journal:  Unfallchirurgie       Date:  1994-12

3.  Anti-vWf antibodies induce GPIbalpha and FcgammaRII mediated platelet aggregation only at low shear forces.

Authors:  M F Hoylaerts; A Viaene; C Thys; H Deckmyn; J Vermylen
Journal:  J Thromb Thrombolysis       Date:  2001-12       Impact factor: 2.300

4.  Platelet activation following intravenous injection of a conventional heparin: absence of effect with a low molecular weight heparinoid (Org 10172).

Authors:  D P Mikhailidis; V A Fonseca; M A Barradas; J Y Jeremy; P Dandona
Journal:  Br J Clin Pharmacol       Date:  1987-10       Impact factor: 4.335

5.  [Sinus vein thrombosis. A rare complication of heparin-induced thrombocytopenia type II].

Authors:  S Merz; R Fehr; C Gülke
Journal:  Anaesthesist       Date:  2004-06       Impact factor: 1.041

Review 6.  Low molecular weight heparins. An objective overview.

Authors:  D Hoppensteadt; J M Walenga; J Fareed
Journal:  Drugs Aging       Date:  1992 Sep-Oct       Impact factor: 3.923

7.  Rapid, Label-free Optical Spectroscopy Platform for Diagnosis of Heparin-Induced Thrombocytopenia.

Authors:  Zufang Huang; Soumik Siddhanta; Gang Zheng; Thomas Kickler; Ishan Barman
Journal:  Angew Chem Int Ed Engl       Date:  2020-02-19       Impact factor: 15.336

Review 8.  Prevention and treatment of venous thromboembolism.

Authors:  G F Pineo; R D Hull
Journal:  Drugs       Date:  1996-07       Impact factor: 9.546

9.  Heparin-induced thrombocytopenia with associated thrombosis in children after the Fontan operation: report of two cases.

Authors:  Rosalia Porcelli; Bonnie C Moskowitz; Frank Cetta; Lynn C Graham; John E Godwin; Benjamin W Eidem; M Margaret Prechel; Jeanine M Walenga
Journal:  Tex Heart Inst J       Date:  2003

Review 10.  Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins.

Authors:  M Verstraete
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.